Regencell Bioscience Holdings Limited (RGC) vs Xenon Pharmaceuticals Inc. (XENE)
A side-by-side comparison of Regencell Bioscience Holdings Limited and Xenon Pharmaceuticals Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
RGC
Regencell Bioscience Holdings Limited
$7.56HealthcareDelayed quote: Oct 6, 2026, 1:49 PM EDT
XENE
Xenon Pharmaceuticals Inc.
$36.05HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — RGC vs XENE
growth of $100 · dividends reinvested · last 5yRGC +2520.2% (+92.2%/yr)XENE +112.4% (+16.3%/yr)RGC compounded faster over this window
Log scale — wide-divergence pair
RGC XENE
RGC vs XENE: by the numbers
- •RGC is the larger company ($3.75B vs $3.48B market cap).
- •Both run net losses; RGC's is the smaller (0.00% vs -4612.13% net margin).
Metrics side by side
Valuation
| Metric | RGC | XENE |
|---|---|---|
| P/B ratio | 3071.87 | 2.80 |
Profitability
| Metric | RGC | XENE |
|---|---|---|
| Gross margin | 0.00% | 66.09% |
| Operating margin | 0.00% | -4974.27% |
| Net margin | 0.00% | -4612.13% |
| ROE | -73.75% | -32.94% |
| ROIC | -69.75% | -35.27% |
Growth (annualized)
| Metric | RGC | XENE |
|---|---|---|
| Total return CAGR (5Y) | 67.94% | 4.61% |
Frequently asked
- How have RGC and XENE total returns compared?
- Over the past 5 years, RGC delivered 67.94% and XENE delivered 4.61% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Regencell Bioscience ROEXenon Pharmaceuticals ROERegencell Bioscience operating marginXenon Pharmaceuticals operating marginRegencell Bioscience revenue growthXenon Pharmaceuticals revenue growthRegencell Bioscience free cash flowXenon Pharmaceuticals free cash flow
Regencell Bioscience & Xenon Pharmaceuticals appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.